Max Robotics — Global Service Robot Directory + US Certification

About

Matthew Ho is a leading urologic oncologist whose research focuses on the surgical management of testicular and genitourinary cancers, with a particular emphasis on robotic-assisted techniques. His most impactful work, the worldwide multicenter study on robotic postchemotherapy retroperitoneal lymph node dissection (RPC-RPLND), has garnered 10 citations since its 2024 publication, establishing a new benchmark for minimally invasive oncological outcomes. Ho’s major contribution lies in demonstrating that robotic RPC-RPLND can achieve comparable oncological efficacy to traditional open surgery while reducing perioperative morbidity—a paradigm shift in treating advanced testicular cancer. His research has been instrumental in validating the safety and feasibility of robotic approaches in complex postchemotherapy settings, directly influencing clinical guidelines and expanding surgical options for patients. Beyond this landmark study, Ho has published extensively on surgical innovation and outcomes in urologic oncology, with his work cited in leading journals and integrated into international practice patterns. His dedication to advancing minimally invasive techniques and improving long-term survival rates marks him as a transformative figure in the field, making his research essential reading for surgeons and oncologists seeking to optimize care for testicular cancer patients.